Atlas Trials

Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL

Clinical trial NCT04491721 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT04491721
Sponsor
Chinese Academy of Medical Sciences
Status
ENROLLING_BY_INVITATION
Study type
OBSERVATIONAL
Diffuse Large B Cell Lymphoma
Start date
2020-07-01
Primary completion
2027-06-01
Enrollment
407

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.